Super-absorbent, reduced-pressure wound dressing and systems

Information

  • Patent Grant
  • 11793679
  • Patent Number
    11,793,679
  • Date Filed
    Friday, May 15, 2020
    4 years ago
  • Date Issued
    Tuesday, October 24, 2023
    a year ago
Abstract
A super-absorbent dressing assembly for use with a reduced-pressure wound treatment system includes a breathable, fluid restricted dry layer for placement against a wound, a super-absorbent layer, and a non-breathable layer, and a drape extending over the non-breathable layer. A reduced-pressure interface is available to fluidly couple the super-absorbent layer to a reduced-pressure subsystem. The super-absorbent dressing assembly preferably supplies a compressive force when placed under reduced pressure. A reduced-pressure treatment system uses a super-absorbent bolster to treat wounds, e.g., linear wounds.
Description
BACKGROUND

The present invention relates generally to medical treatment systems, and more particularly, to super-absorbent, reduced-pressure wound dressings and systems suitable for use with wounds such as surgical wounds.


Physicians perform millions of surgical procedures each year around the world. Many of the procedures are performed as open surgery and an increasing number are performed using minimally invasive surgery, such as endoscopic, arthroscopic, and laparoscopic procedures. As one example, the American Society for Aesthetic Plastic Surgery reports that there were more than 450,000 liposuction procedures in the United States in 2007.


Surgical procedures involve acute wounds, e.g., an incision, in the epidermis and related tissue. In many instances, the incision is closed at the conclusion of the procedure using a mechanical apparatus, such as staples or suture, or closed using adhesives. Thereafter, the wound is often merely covered with a dry, sterile bandage. Of course, there is usually more disruption than just at the epidermis.


With many surgical procedures, particularly those done with minimally invasive techniques, much of the disruption or damage is below the epidermis, or at a subcutaneous level. Again, as one example, in one type of liposuction procedure, after the introduction of a tumescent fluid (saline, mild painkiller, and epinephrine), the surgeon will use a trocar and cannula with suction to remove fatty areas. In doing so, it is not uncommon to have subcutaneous voids and other tissue defects formed at tissue sites remote from the incision through which the cannula was placed or other incisions through which equipment was placed. The damaged tissue will need time and care to heal and poses a number of potential complications and risks including edema, seroma, hematoma, further bruising, and ecchymosis to name some.


To facilitate healing after many surgical procedures, such as liposuction, depending on the body part involved, a firm-fitting wrap or elastic compression garment may be used for weeks on the patient. These devices are at times uncomfortable, may apply compression in a non-uniform manner, and can be difficult to take off and put on. In addition, because of edema, a number of different compression garments may be required for a single patient. It would be desirable to address some or all of the shortcomings of post-surgical wound care at the incision and at the undermined subcutaneous tissue.


BRIEF SUMMARY

The illustrative embodiments herein may be used with wounds, or irregular tissue, including area wounds and linear wounds. “Linear wound” refers generally to a laceration or incision whether in a line or not. According to an illustrative embodiment, a dressing assembly for use with a reduced-pressure treatment system includes a breathable, fluid restricted dry layer for placement against a wound on a patient and having a first surface and a second, inward-facing surface. The dressing assembly further includes a super-absorbent layer having a first surface and second, inward-facing surface. The second, inward-facing surface of the super-absorbent layer is disposed adjacent to the first surface of the breathable dry layer. The dressing assembly further includes a non-breathable layer having a first surface and a second, inward-facing surface. The second, inward-facing surface of the non-breathable layer is disposed adjacent to the first surface of the super-absorbent layer.


According to one illustrative embodiment, a reduced-pressure treatment system for treating a wound includes a super-absorbent bolster for placing on the patient's epidermis and substantially sized to overlay the wound. The super-absorbent bolster is operable to manifold reduced pressure. The reduced-pressure treatment system further includes a sealing subsystem for providing a fluid seal between the super-absorbent dressing bolster and the patient and a reduced-pressure subsystem for delivering reduced pressure to the sealing subsystem. The sealing subsystem and reduced-pressure subsystem are operable to deliver reduced pressure to the wound. The super-absorbent dressing bolster, sealing subsystem, and reduced-pressure subsystem are operable to develop a compressive force.


According to one illustrative embodiment, a system for assisting the healing of a wound on a patient includes a super-absorbent bolster assembly for placing on the wound of the patient, a sealing subsystem for providing a fluid seal over the super-absorbent bolster assembly and the patient, and a reduced-pressure subsystem for delivering a reduced pressure to the sealing subsystem. The super-absorbent bolster, sealing subsystem, and reduce-pressure subsystem are operable to deliver reduced pressure to the wound and remove exudate from the wound. The super-absorbent bolster may be operable to hold more than 250 milliliters of fluid while presenting a dry, inward-facing surface. The absorbent bolster assembly includes a breathable, fluid restricted dry layer having a first surface and a second, inward-facing surface and a super-absorbent layer having a first surface and second, inward-facing surface. The second, inward-facing surface of the super-absorbent layer is disposed adjacent to the first surface of the breathable dry layer.


Other objects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and the detailed description that follow.





BRIEF DESCRIPTION OF THE DRAWINGS

A more complete understanding of the present invention may be obtained by reference to the following Detailed Description when taken in conjunction with the accompanying Drawings wherein:



FIG. 1 is a schematic, cross-section (with a portion shown in elevation view) of an illustrative embodiment of a reduced-pressure treatment system for treating a wound;



FIG. 2 is an exploded schematic, cross-section of an illustrative embodiment of a dressing assembly for use with a reduced-pressure wound treatment system;



FIG. 3 is schematic, top view of a portion of illustrative embodiment of a dressing assembly for use with a reduced-pressure wound treatment system; and



FIG. 4 is schematic, top view of a portion of another illustrative embodiment of a dressing assembly for use with a reduced-pressure wound treatment system.





DETAILED DESCRIPTION

In the following detailed description of the preferred embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown, by way of illustration, specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the invention, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined only by the appended claims.


Referring to FIG. 1, an illustrative embodiment of a reduced-pressure treatment system 10 for treating a wound, e.g., a linear wound, is presented. With the system 10, exudate and fluids are held by a dressing bolster to an extent that a portable reduced-pressure source may not need a storage canister. The system 10 may develop a compression force that is applied against a portion of the patient and that may be controlled in real time. The system 10 may be used with linear wounds 12 (e.g., an incision), area wounds, grafts, or subcutaneous voids. Among other things, when applied, the system 10 may help stabilize or hold tissue, enhance tensile strength of a wound, compress subcutaneous tissue to help reduce dead space, isolate the wound from external infectious sources, or enhance perfusion. Tensile strength of the wound means the strength of the wound as a force attempts to pull the wound apart or open. Unless otherwise indicated, as used herein, “or” does not require mutual exclusivity.


The reduced-pressure treatment system 10 is shown in the region of the linear wound 12, which is an incision through epidermis 14 and dermis 16 and reaching into a hypodermis or subcutaneous tissue 18. The subcutaneous tissue 18 may include numerous tissue types such as fatty tissue or muscle. An undermined subcutaneous tissue 20 is shown extending out from the linear wound 12 and includes, in this instance, a subcutaneous defect, dead space, or void 22. The undermined subcutaneous tissue 20 is often caused by surgical procedures such as liposuction. The undermined subcutaneous tissue 20 may include voids (such as void 22), open spaces, and various defects that can be troublesome for a number of reasons such as allowing fluids to build that may result in edema.


The linear wound 12 may be closed using any closing device such as staples, sutures, or adhesive, but is shown in this embodiment with suture 13. The reduced-pressure treatment system 10 is for treating a linear wound, such as linear wound 12, which is an incision in this illustration. The reduced-pressure treatment system may also be used to treat the subcutaneous tissue 20, an area wound, or a graft.


The reduced-pressure treatment system 10 includes a super-absorbent dressing assembly 30, which includes a super-absorbent dressing bolster 31; a sealing subsystem 60; and a reduced-pressure subsystem 80. When reduced pressure is supplied to the super-absorbent dressing bolster 31, the super-absorbent dressing bolster 31 distributes the reduced pressure to the linear wound 12, develops a compressive force 24, removes fluid, such as exudate, from the linear wound 12, and substantially holds (or stores) all the removed fluid. The reduced-pressure system 10 is operable to deliver reduced pressure to the linear wound 12 that is realized at the level of the subcutaneous tissue 22 and helps approximate—bring together—the tissues in that region as well as helping to remove any air or any other fluids.


The super-absorbent dressing assembly 30 includes a super-absorbent bolster 31 having a super-absorbent layer 32, which has a first surface 34 and a second, inward-facing surface 36; an entry layer 38 (or fluid entry layer), which has a first surface 40 and a second, inward-facing surface 42, and which may be a breathable, fluid restricted dry layer for placement against the linear wound 12; and a top layer 44, which has a first surface 46 and a second, inward-facing surface 48, and which may be a non-breathable layer. The super-absorbent dressing bolster 31 is sized and shaped to substantially extend over the linear wound 12, and if used in an area application, the super-absorbent dressing bolster 31 is sized to substantially match the estimated area of undermined subcutaneous tissue 20 although a larger or smaller size may be used in different applications. The super-absorbent layer 32 is further described below.


“Breathable” as used herein means gas permeable. The breathable, fluid restricted dry layer allow a gas to permeate and restricts fluid as will be described. That the breathable, fluid restricted dry layer is “fluid restricted” means that it allows fluid to enter, e.g. exudate from the wound may pass through the layer, but the liquid does not generally flow the other direction. This means that the bottom surface of the breathable, fluid restricted dry layer remains dry to the touch. The breathable, fluid restricted dry layer is analogous to the layer of a typical disposable diaper that is next to a baby's skin.


The super-absorbent dressing bolster 31 is operable to distribute reduced pressure to the linear wound 12 and develop forces. The term “manifold” as used herein generally refers to a substance or structure that is provided to assist in applying reduced pressure to, delivering fluids to, or removing fluids from a tissue site. A manifold typically includes a plurality of flow channels or pathways that are interconnected to improve distribution of fluids provided to and removed from the area of tissue around the manifold.


The sealing subsystem 60 includes a drape 62, or sealing member. The drape 62 may be any material that provides a fluid seal, such as an elastomeric material. “Fluid seal,” or “seal,” means a seal adequate to hold reduced pressure at a desired site given the particular reduced-pressure subsystem involved. “Elastomeric” means having the properties of an elastomer. It generally refers to a polymeric material that has rubber-like properties. More specifically, most elastomers have elongation rates greater than 100% and a significant amount of resilience. The resilience of a material refers to the material's ability to recover from an elastic deformation. Examples of elastomers may include, but are not limited to, natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, and silicones. Specific examples of the drape materials include a silicone drape, 3M Tegaderm® drape, acrylic drape such as ones available from Avery Dennison, or an incise drape.


The drape 62 may be coupled to the super-absorbent dressing bolster 31 and in particular to the first surface 46 of the top layer 44. The coupling may occur in many ways. The drape 62 and the top layer 44 may be coupled using adhesives such as by acrylic adhesive, silicone adhesive, hydrogel, hydrocolloid, etc. The drape 62 and the top layer 44 may be bonded by heat bonding, ultrasonic bonding, and radio frequency bonding, etc. The coupling may occur in patterns, more completely, or totally. Structural members may be added to the bond to make the drape 62 behave anisotropically in a desired direction, i.e. to make an anisotropic drape material. The anisotropic drape material helps the dressing assembly 30 to primarily move in a given direction, i.e. only about a certain axis or axes.


In the embodiment of FIG. 1, the drape 62 is sized to extend beyond a peripheral edge 39 of the super-absorbent dressing bolster 31 and thereby to form a drape extension 64. The drape extension 64 has a first surface 66 and a second, inward-facing surface 68. The drape 62 may be sealed against the patient's epidermis 14 using a sealing apparatus 69 for providing a fluid seal, which allows a reduced pressure to be maintained by the reduced-pressure subsystem 80. The sealing apparatus 69 may take numerous forms such as adhesive, a sealing tape 70, or drape tape or strip, double-side drape tape, paste, hydrocolloid, hydrogel, or other sealing means. If a tape 70 is used, the tape 70 may be formed of the same material as the drape 62 with a pre-applied, pressure-sensitive adhesive. In another embodiment, a pressure sensitive adhesive may be applied on the second surface 68 of the drape extension 64. The adhesive provides a substantially fluid seal between the drape 62 and the epidermis 14 of the patient. Before the drape 62 is secured to the patient, the adhesive may have removable strips covering the pressure-sensitive adhesive. In using the tape 70, the tape 70 is applied over the extension 64 to provide a fluid seal.


The reduced-pressure subsystem 80 includes a reduced-pressure source 82, which can take many different embodiments that provide a reduced pressure as a part of the reduced-pressure treatment system 10. The reduced-pressure source 82 may be any device for supplying a reduced-pressure, such as a vacuum pump, wall suction, or other source. While the amount and nature of reduced-pressure applied to a tissue site will typically vary according to the application, the reduced-pressure will typically be between −5 mm Hg and −500 mm Hg and more typically between −100 mm Hg and −300 mm Hg. A pressure of −200 mm Hg may be used in some situations.


As used herein, “reduced-pressure” generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced-pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced-pressure may be less than a hydrostatic pressure at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. The reduced-pressure delivered may be constant or varied (patterned or random) and may be delivered continuously or intermittently. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to the tissue site, the actual pressure applied to the tissue site may be more than the pressure normally associated with a complete vacuum. Consistent with the use herein, an increase in reduced-pressure or vacuum pressure typically refers to a relative reduction in absolute pressure.


In order to maximize patient mobility and ease, the reduced-pressure source 82 may be a battery-powered, single-use reduced-pressure generator, or therapy unit. Such a pressure source 82 facilitates application in the operating room and provides mobility and convenience for the patient during the rehabilitation phase. Other sources of reduced pressure may be utilized such as V.A.C.® therapy unit, which is available from KCI of San Antonio, Texas, or a wall suction unit. The reduced-pressure source could also be supplied by a portable mechanical device, such as a piston in a tube, depending on how much leakage there is with the fluid seal between the dressing bolster and the epidermis.


The super-absorbent nature of the super-absorbent dressing bolster 31 allows for the possibility of utilizing a reduced-pressure source that does not require a remote fluid-storage canister because the super-absorbent dressing bolster 31 effectively stores the fluid. The super-absorbent layer 32 may hold 300 milliliters of fluid or more. At the same time, entry layer 38 keeps the fluid away from the patient's epidermis 14 so that maceration may be avoided. The reduced-pressure source 82 is shown having a battery compartment 84. An interposed membrane filter, such as hydrophobic or oleophobic filter, may be interspersed between a reduced-pressure delivery conduit, or tubing, 90 and the reduced-pressure source 82.


The reduced pressure developed by the reduced-pressure source 82 is delivered through the reduced-pressure conduit 90 to a reduced-pressure interface 92, which may be an elbow port 94. In one embodiment, the elbow port 94 is a TRAC® technology port available from KCI of San Antonio, Texas The reduced-pressure interface 92 allows reduced pressure to be delivered to the sealing subsystem 60 and realized within an interior portion of sealing subsystem 60. In this particular embodiment, the reduced-pressure interface 92 extends through the drape 62 and into the super-absorbent dressing bolster 31.


In operation, the reduced-pressure treatment system 10 may be applied in the operating room after a surgical procedure on the patient or elsewhere. The second surface 42 of the entry layer 38 of the super-absorbent dressing bolster 31 would be placed against the patient's epidermis 14 over the linear wound 12. The dressing assembly 30 may be sized for typical application involved in the procedure performed by a healthcare provider. The dressing assembly 30 may be sized, shaped, and configured to work in different anatomical applications such as abdomen, chest, thighs, hip, etc.


If the drape 62 is not already coupled to the super-absorbent dressing bolster 31, the drape 62 is placed over the first surface 46 of the top layer 44 and the peripheral edge 39 of the super-absorbent dressing bolster 31 with an extra portion extending beyond the peripheral edge 39 to form the drape extension 64. The drape extension 64 can then be taped down with the tape 70 or an adhesive used to form a fluid seal between the drape 62 and the patient's epidermis 14. The fluid seal need only be adequate to allow the reduced-pressure treatment system 10 to maintain a reduced pressure on the treatment area or tissue site for a desired treatment time. The reduced-pressure interface 92 is applied if not already installed. The reduced-pressure delivery conduit 90 is fluidly coupled to the reduced-pressure source 82 and the reduced-pressure interface 92. The reduced-pressure source 82 may then be activated and a reduced pressure delivered to the super-absorbent dressing bolster 31.


As the pressure is reduced at the super-absorbent dressing bolster 31, the reduced pressure is transmitted further still through the super-absorbent dressing bolster 31 so that the reduced pressure is experienced at the patient's epidermis 14 proximate the linear wound 12. At least at the early stages of the healing process, the reduced pressure may be realized through the linear wound 12 and into the subcutaneous tissue 20 and, if so, the reduced pressure helps close defects (if any) such as the subcutaneous void 22 and generally provides stability to the treatment area. The reduced pressure delivered to the super-absorbent dressing bolster 31 also develops a compressive force 24 that again provides stability and may enhance tensile strength, etc. The compressive force 24 may be more than just at the top of the epidermis 14. The compressive force may extend down deeper and may be experienced at the level of the subcutaneous tissue 20.


During treatment, care is taken to avoid skin irritation, such as blistering of the patient's epidermis 14, due to secondary shear, secondary strain or other effects. To help avoid skin irritation, the peripheral edge 39 may be shaped or angled or an inner layer may be added between the super-absorbent dressing bolster 31 and the patient's epidermis 14.


Referring now to FIG. 2, an exploded, schematic cross-section of a portion of a super-absorbent dressing assembly 130 for use with a reduced-pressure wound treatment system is shown. The super-absorbent dressing assembly 130 is analogous in most respect to the super-absorbent dressing assembly 30 of FIG. 1, but the super-absorbent dressing assembly 130 is shown without a drape extending over the super-absorbent dressing assembly 130. The super-absorbent dressing assembly 130 may include a number of layers, but is shown in this illustrative embodiment as having a super-absorbent dressing bolster 131 that includes three main layers: a super-absorbent layer 132, an entry layer 138, and a top layer 144.


The entry layer 138 has a first surface 140 and a second, inward-facing surface 142. The entry layer 138 is intended to allow fluid to leave a linear wound 112 on the patient's epidermis 114 and pass through the entry layer 138, but not remain on the epidermis 114. In other words, the entry layer 138 functions to effectively allow flow in only one direction. This one-way action helps to avoid maceration of the epidermis 114. The entry layer 138 also helps manifold, or distribute, reduced pressure to the linear wound 112. The entry layer 138 may be described as a breathable dry layer. Many materials may be used for the entry layer 138 such as a hydrophilic non-woven material.


The top layer 144 has a first surface 146 and a second, inward-facing surface 148. The top layer 144 may be a non-breathable layer. The top layer 144 may have an aperture 149 formed through the top layer 144 to accommodate a reduced-pressure fluidly coupled to a reduced-pressure source. The top layer 144 helps provide a seal over the super-absorbent layer 132. A number of materials may be used for the top layer 144 such as a polyethylene film that will keep fluids from leaking out. In an alternative embodiment, the top layer 144 may be omitted and a drape alone used to contain fluids within the super-absorbent dressing assembly 130.


An additional interface breathable layer 194 may added on the first surface 146 of the top layer 144 to function as a filter. The interface breathable layer 194 covers aperture 149. The interface breathable layer 194 allows delivery of reduced pressure and prevents portions of the super-absorbent layer 132 from entering the reduced-pressure interface, e.g., reduced-pressure interface 92 of FIG. 1, that rests on top of the super-absorbent dressing assembly 130.


The super-absorbent layer 132 has a first surface 134 and a second, inward-facing surface 136. The super-absorbent layer 132 helps manifold reduced pressure to the entry layer 138 and on to the linear wound 112. The super-absorbent layer 132 is operable to hold relatively large quantities of fluid and is operable to help serve as a dressing bolster for developing a compressive force (e.g., force 24 in FIG. 1).


The super-absorbent layer 32 (FIG. 1) and the super-absorbent layer 132 may be formed from superabsorbent polymers (SAP) of the type often referred to as “hydrogels,” “super-absorbents,” or “hydrocolloids.” Super-absorbent spheres may be used as well that would manifold reduced pressure until the super-absorbent spheres become saturated. In order to allow a reduced pressure to be used without a remote canister or with a relatively small remote canister in a human patient, it is desirable with many surgical applications to make the super-absorbent layer 132 operable to hold at least 300 milliliters of fluid. It some applications, it may additionally be desirable to provide super-absorbent material in the reduced-pressure deliver conduit (e.g., 90 in FIG. 1) between the super-absorbent dressing 132 and the reduced-pressure source to further hold fluid.


When fluid is added to the super-absorbent layer 132, the dressing bolster 131 becomes more rigid and under reduced pressure this results in an increased compressive force, such as force 24 in FIG. 1. The fluid may come in the form of exudates or other fluids from the linear wound 112 or may be a supplied fluid, such as a saline, that is intentionally added by injection or otherwise.


Referring now to FIG. 3, a super-absorbent dressing assembly 230 may be formed with a reduced-pressure interface 292 for delivering reduced pressure and an injection port 233. The injection port 233 facilitates injection of a fluid into a super-absorbent layer of the super-absorbent dressing assembly 230.


Referring now to FIG. 4, a super-absorbent dressing assembly 330 may have a first interface 392, or reduced-pressure interface, for delivering a reduced pressure to a super-absorbent layer, and may also include a second interface 335, or a fluid delivery interface, for delivering a fluid, such as saline, to the super-absorbent layer.


Whether by an injection port 233 (FIG. 3) or a second interface 335 (FIG. 4) or another means, fluid may be added to the super-absorbent layer to increase the rigidity of the super-absorbent layer and this provides a liquid-controlled bolster. The addition of liquid controls the rigidity which in turn can control the compressive force developed under reduced pressure. If the fluid is supplied from a exudating (e.g., bleeding) wound, the additional compressive force developed with additional fluid-exudate-helps make the dressing somewhat self-adjusting or self-regulating. This may be particularly useful in wound treatment on the battlefield. The amount of compression developed may also be influenced by the elasticity of the drape; the more stretchable it is, the less compressive force will be developed. A transducer and controller may be provided that facilitates measurement of the compression force and is able to adjust the quantity of fluid supplied through the second interface 335 (or remove through the first interface 392) to regulate the compression at a desired level or within desired parameters.


According to another illustrative embodiment, a method of manufacturing a dressing assembly for use with a reduced-pressure wound treatment system includes the steps of: forming a breathable, fluid restricted dry layer for placement against a wound and having a first surface and a second, inward-facing surface; disposing a super-absorbent layer having a first surface and second, inward-facing surface adjacent to the breathable dry layer; disposing a non-breathable layer having a first surface and a second, inward-facing surface adjacent to the first surface of the super-absorbent layer. The method of manufacturing further includes placing a drape over the first surface of the non-breathable layer; and fluidly coupling a reduced-pressure interface to the super-absorbent layer.


Although the present invention and its advantages have been disclosed in the context of certain illustrative, non-limiting embodiments, it should be understood that various changes, substitutions, permutations, and alterations can be made without departing from the scope of the invention as defined by the appended claims. It will be appreciated that any feature that is described in a connection to any one embodiment may also be applicable to any other embodiment.

Claims
  • 1. A method of delivering reduced pressure to a wound, the method comprising: disposing a super-absorbent dressing bolster adjacent a patient's epidermis and over the wound, the super-absorbent dressing bolster comprising: an entry layer having a first surface and a second, inward-facing surface,a super-absorbent layer having a first surface and second surface, the second, inward-facing surface of the super-absorbent layer disposed adjacent to the first surface of the entry layer,a top layer having a first surface and a second, inward-facing surface, the second, inward-facing surface of the top layer disposed adjacent to the first surface of the super-absorbent layer, wherein the top layer is a non-breathable layer, anda drape extending over the first surface of the top layer of the dressing bolster;fluidly coupling a reduced-pressure source to the super-absorbent dressing bolster; anddelivering reduced pressure to the super-absorbent dressing bolster.
  • 2. The method of claim 1, wherein the super-absorbent dressing bolster develops a compressive force that is greater with the addition of fluid to the super-absorbent layer.
  • 3. The method of claim 1, wherein the super-absorbent dressing bolster further comprises a drape extension formed by a portion of the drape extending beyond a peripheral edge of the entry layer, the super-absorbent layer, and the top layer.
  • 4. The method of claim 3, wherein the drape extending beyond the peripheral edge of the dressing bolster forms the drape extension.
  • 5. The method of claim 4, further comprising sealing the drape extension to the patient's epidermis using a sealing apparatus to form a fluid seal.
  • 6. The method of claim 5, wherein the sealing apparatus is an adhesive.
  • 7. The method of claim 5, wherein the sealing apparatus is a tape.
  • 8. The method of claim 1, further comprising fluidly coupling a reduced-pressure interface to the super-absorbent dressing bolster.
  • 9. The method of claim 8, further comprising fluidly coupling a reduced-pressure delivery conduit to the reduced-pressure interface and the reduced-pressure source.
  • 10. The method of claim 8, wherein the super-absorbent dressing bolster further comprises an interface breathable layer disposed adjacent the first surface of the top layer.
  • 11. The method of claim 10, wherein the interface breathable layer is configured to allow delivery of reduced pressure and prevent material from entering the reduced-pressure interface.
  • 12. The method of claim 1, further comprising fluidly coupling a fluid delivery interface to the super-absorbent dressing bolster for delivering fluid to the super-absorbent layer.
  • 13. The method of claim 1, wherein the entry layer is a fluid-restricted dry layer.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/309,705, filed Jun. 19, 2014, which is a continuation of U.S. patent application Ser. No. 13/546,161, filed Jul. 11, 2012, now U.S. Pat. No. 8,795,244, which is a divisional of U.S. patent application Ser. No. 12/475,285 filed May 29, 2009, now U.S. Pat. No. 8,241,261, which claims the benefit, under 35 U.S.C. § 119(e), of U.S. Provisional Patent Application No. 61/057,807, entitled “Reduced-pressure Surgical Wound Treatment System,” filed May 30, 2008; U.S. Provisional Patent Application No. 61/057,798, entitled “Dressing Assembly For Subcutaneous Wound treatment Using Reduce Pressure,” filed May 30, 2008; U.S. Provisional Patent Application No. 61/057,808, entitled “See-Through, Reduced-Pressure Dressing,” filed May 30, 2008; U.S. Provisional Patent Application No. 61/057,802, entitled “Reduced-Pressure Dressing Assembly For Use in Applying a Closing Force,” filed May 30, 2008; U.S. Provisional Patent Application No. 61/057,803, entitled “Reduced-Pressure, Linear-Wound Treatment System,” filed May 30, 2008; U.S. Provisional Patent Application No. 61/057,800, entitled “Reduced-Pressure, Compression System and Apparatus for use on a Curved Body Part,” filed, May 30, 2008; U.S. Provisional Patent Application No. 61/057,797, entitled “Reduced-Pressure, Compression System and Apparatus for use on Breast Tissue,” filed May 30, 2008; U.S. Provisional Patent Application No. 61/057,805, entitled “Super-Absorbent, Reduced-Pressure Wound Dressing and System,” filed May 30, 2008; U.S. Provisional Patent Application No. 61/057,810, entitled “Reduced-Pressure, Compression System and Apparatus for use on a Joint,” filed May 30, 2008; U.S. Provisional Patent Application No. 61/121,362, entitled “Reduced-Pressure Wound treatment System Employing an Anisotropic Drape,” filed Dec. 10, 2008; and U.S. Provisional Patent Application No. 61/144,067, entitled “Reduced-Pressure, Compression System and Apparatus for use on a Joint,” filed Jan. 12, 2009, all of which applications are incorporated herein by reference for all purposes.

US Referenced Citations (301)
Number Name Date Kind
1195430 Angier Aug 1916 A
1355846 Rannells Oct 1920 A
1638043 Lee Aug 1927 A
1845630 Scholl Feb 1932 A
2452345 Anselmo Oct 1948 A
2547758 Keeling Apr 1951 A
2632443 Lesher Mar 1953 A
2682873 Evans et al. Jul 1954 A
2896618 Schaefer Jul 1959 A
2910763 Lauterbach Nov 1959 A
2969057 Simmons Jan 1961 A
3026874 Stevens Mar 1962 A
3066672 Crosby, Jr. et al. Dec 1962 A
3367332 Groves Feb 1968 A
3419006 Warwick Dec 1968 A
3520300 Flower, Jr. Jul 1970 A
3568675 Harvey Mar 1971 A
3648692 Wheeler Mar 1972 A
3682180 McFarlane Aug 1972 A
3826254 Mellor Jul 1974 A
3892229 Taylor et al. Jul 1975 A
3903882 Augurt Sep 1975 A
3969561 Marshall Jul 1976 A
4080970 Miller Mar 1978 A
4091804 Hasty May 1978 A
4096853 Weigand Jun 1978 A
4121582 Masso Remiro Oct 1978 A
4139004 Gonzalez, Jr. Feb 1979 A
4165748 Johnson Aug 1979 A
4184510 Murry et al. Jan 1980 A
4224945 Cohen Sep 1980 A
4233969 Lock et al. Nov 1980 A
4245630 Lloyd et al. Jan 1981 A
4256109 Nichols Mar 1981 A
4261363 Russo Apr 1981 A
4266545 Moss May 1981 A
4275721 Olson Jun 1981 A
4284079 Adair Aug 1981 A
4297995 Golub Nov 1981 A
4333468 Geist Jun 1982 A
4373519 Errede et al. Feb 1983 A
4375217 Arkans Mar 1983 A
4382441 Svedman May 1983 A
4392853 Muto Jul 1983 A
4392858 George et al. Jul 1983 A
4419097 Rowland Dec 1983 A
4430998 Harvey et al. Feb 1984 A
4465485 Kashmer et al. Aug 1984 A
4475909 Eisenberg Oct 1984 A
4480638 Schmid Nov 1984 A
4525166 Leclerc Jun 1985 A
4525374 Vaillancourt Jun 1985 A
4540412 Van Overloop Sep 1985 A
4543100 Brodsky Sep 1985 A
4548202 Duncan Oct 1985 A
4551139 Plaas et al. Nov 1985 A
4569348 Hasslinger Feb 1986 A
4572814 Naylor et al. Feb 1986 A
4605399 Weston et al. Aug 1986 A
4608041 Nielsen Aug 1986 A
4612230 Liland et al. Sep 1986 A
4640688 Hauser Feb 1987 A
4655754 Richmond et al. Apr 1987 A
4663352 Onofrj May 1987 A
4664662 Webster May 1987 A
4710165 McNeil et al. Dec 1987 A
4722332 Saggers Feb 1988 A
4727868 Szycher et al. Mar 1988 A
4733659 Edenbaum et al. Mar 1988 A
4743232 Kruger May 1988 A
4751133 Szycher et al. Jun 1988 A
4758220 Sundblom et al. Jul 1988 A
4770490 Gruenewald et al. Sep 1988 A
4787888 Fox Nov 1988 A
4795435 Steer Jan 1989 A
4826494 Richmond et al. May 1989 A
4838883 Matsuura Jun 1989 A
4840187 Brazier Jun 1989 A
4863449 Therriault et al. Sep 1989 A
4865026 Barrett Sep 1989 A
4872450 Austad Oct 1989 A
4878901 Sachse Nov 1989 A
4897081 Poirier et al. Jan 1990 A
4902565 Brook Feb 1990 A
4906233 Moriuchi et al. Mar 1990 A
4906240 Reed et al. Mar 1990 A
4917112 Kalt Apr 1990 A
4919654 Kalt Apr 1990 A
4941882 Ward et al. Jul 1990 A
4953565 Tachibana et al. Sep 1990 A
4969880 Zamierowski Nov 1990 A
4985019 Michelson Jan 1991 A
5000741 Kalt Mar 1991 A
5018515 Gilman May 1991 A
5037397 Kalt et al. Aug 1991 A
5086170 Luheshi et al. Feb 1992 A
5092858 Benson et al. Mar 1992 A
5100396 Zamierowski Mar 1992 A
5106629 Cartmell et al. Apr 1992 A
5134994 Say Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5160315 Heinecke et al. Nov 1992 A
5167613 Karami et al. Dec 1992 A
5176663 Svedman et al. Jan 1993 A
5215522 Page et al. Jun 1993 A
5232453 Plass et al. Aug 1993 A
5261893 Zamierowski Nov 1993 A
5278100 Doan et al. Jan 1994 A
5279550 Habib et al. Jan 1994 A
5298015 Komatsuzaki et al. Mar 1994 A
5306798 Horn et al. Apr 1994 A
5342376 Ruff Aug 1994 A
5344415 DeBusk et al. Sep 1994 A
5358494 Svedman Oct 1994 A
5376067 Daneshvar Dec 1994 A
5380294 Persson Jan 1995 A
5423737 Cartmell et al. Jun 1995 A
5429593 Matory Jul 1995 A
5435009 Schild et al. Jul 1995 A
5437622 Carion Aug 1995 A
5437651 Todd et al. Aug 1995 A
5489262 Cartmell et al. Feb 1996 A
5497788 Inman et al. Mar 1996 A
5520629 Heinecke et al. May 1996 A
5527293 Zamierowski Jun 1996 A
5538502 Johnstone Jul 1996 A
5549584 Gross Aug 1996 A
5556375 Ewall Sep 1996 A
5607388 Wall Mar 1997 A
5628230 Flam May 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5653244 Shaw Aug 1997 A
5714225 Hansen et al. Feb 1998 A
5792088 Felder et al. Aug 1998 A
5844013 Kenndoff et al. Dec 1998 A
5866249 Yarusso et al. Feb 1999 A
5944017 Tweedle Aug 1999 A
5950238 Klein Sep 1999 A
5973221 Collyer et al. Oct 1999 A
6071267 Zamierowski Jun 2000 A
6086450 Mankovitz Jul 2000 A
6109267 Shaw et al. Aug 2000 A
6135116 Vogel et al. Oct 2000 A
6162960 Klein Dec 2000 A
6176868 Detour Jan 2001 B1
6213840 Han Apr 2001 B1
6241747 Ruff Jun 2001 B1
6270910 Jaeger et al. Aug 2001 B1
6287316 Agarwal et al. Sep 2001 B1
6320093 Augustine et al. Nov 2001 B1
6345623 Heaton et al. Feb 2002 B1
6361397 Mankovitz et al. Mar 2002 B1
6420622 Johnston et al. Jul 2002 B1
6426931 Parienti Jul 2002 B1
6440093 McEwen et al. Aug 2002 B1
6458109 Henley et al. Oct 2002 B1
6488643 Tumey et al. Dec 2002 B1
6493568 Bell et al. Dec 2002 B1
6500112 Khouri Dec 2002 B1
6528697 Knutson et al. Mar 2003 B1
6553998 Heaton et al. Apr 2003 B2
6566576 Komerska et al. May 2003 B1
6648862 Watson Nov 2003 B2
6685681 Lockwood et al. Feb 2004 B2
6752794 Lockwood et al. Jun 2004 B2
6814079 Heaton et al. Nov 2004 B2
6824533 Risk, Jr. et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6867342 Johnston et al. Mar 2005 B2
D503509 Bell et al. Apr 2005 S
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
7004915 Boynton et al. Feb 2006 B2
7070584 Johnson et al. Jul 2006 B2
7090647 Mimura et al. Aug 2006 B2
7135007 Scott et al. Nov 2006 B2
7144294 Bell et al. Dec 2006 B2
7195624 Lockwood et al. Mar 2007 B2
7201063 Taylor Apr 2007 B2
7201263 Osada et al. Apr 2007 B2
7214202 Vogel et al. May 2007 B1
7316672 Hunt et al. Jan 2008 B1
7338482 Lockwood et al. Mar 2008 B2
7361184 Joshi Apr 2008 B2
7381859 Hunt et al. Jun 2008 B2
7455681 Wilke et al. Nov 2008 B2
7504549 Castellani et al. Mar 2009 B2
7520872 Biggie et al. Apr 2009 B2
7532953 Vogel May 2009 B2
7534927 Lockwood et al. May 2009 B2
7569742 Haggstrom et al. Aug 2009 B2
7699831 Bengtson et al. Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7846141 Weston Dec 2010 B2
8062273 Weston Nov 2011 B2
8100848 Wilkes et al. Jan 2012 B2
8129580 Wilkes et al. Mar 2012 B2
8216198 Heagle et al. Jul 2012 B2
8241261 Randolph et al. Aug 2012 B2
8251979 Malhi Aug 2012 B2
8257327 Blott et al. Sep 2012 B2
8398614 Blott et al. Mar 2013 B2
8399730 Kazala, Jr. et al. Mar 2013 B2
8449509 Weston May 2013 B2
8529548 Blott et al. Sep 2013 B2
8535296 Blott et al. Sep 2013 B2
8551060 Schuessler et al. Oct 2013 B2
8568386 Malhi Oct 2013 B2
8641691 Fink et al. Feb 2014 B2
8679081 Heagle et al. Mar 2014 B2
8722959 Wilkes et al. May 2014 B2
8834451 Blott et al. Sep 2014 B2
8926592 Blott et al. Jan 2015 B2
9017302 Vitaris et al. Apr 2015 B2
9044579 Blott et al. Jun 2015 B2
9095468 Kazala, Jr. et al. Aug 2015 B2
9198801 Weston Dec 2015 B2
9211365 Weston Dec 2015 B2
9289542 Blott et al. Mar 2016 B2
9456928 Haggstrom et al. Oct 2016 B2
9572719 Long et al. Feb 2017 B2
9750641 Kazala, Jr. et al. Sep 2017 B2
10143593 Kazala, Jr. et al. Dec 2018 B2
10226384 Kazala, Jr. et al. Mar 2019 B2
10568768 Long et al. Feb 2020 B2
20010029956 Argenta et al. Oct 2001 A1
20010043943 Coffey Nov 2001 A1
20020007014 Hyde et al. Jan 2002 A1
20020077661 Saadat Jun 2002 A1
20020115951 Norstrem et al. Aug 2002 A1
20020120185 Johnson Aug 2002 A1
20020143286 Tumey Oct 2002 A1
20030040691 Griesbach et al. Feb 2003 A1
20030109816 Lachenbruch et al. Jun 2003 A1
20030139697 Gilman Jul 2003 A1
20030212359 Butler Nov 2003 A1
20040006319 Lina et al. Jan 2004 A1
20040030304 Hunt et al. Feb 2004 A1
20040039415 Zamierowski Feb 2004 A1
20040064111 Lockwood et al. Apr 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040127836 Sigurjonsson et al. Jul 2004 A1
20040242119 Francis Dec 2004 A1
20040243073 Lockwood et al. Dec 2004 A1
20050059918 Sigurjonsson et al. Mar 2005 A1
20050070858 Lockwood et al. Mar 2005 A1
20050101940 Radl et al. May 2005 A1
20050142331 Anderson et al. Jun 2005 A1
20050209574 Boehringer et al. Sep 2005 A1
20050222544 Weston Oct 2005 A1
20050228329 Boehringer et al. Oct 2005 A1
20060041247 Petrosenko et al. Feb 2006 A1
20060064049 Marcussen Mar 2006 A1
20060079852 Bubb et al. Apr 2006 A1
20060149171 Vogel et al. Jul 2006 A1
20060173253 Ganapathy et al. Aug 2006 A1
20060189910 Johnson et al. Aug 2006 A1
20060213527 Argenta et al. Sep 2006 A1
20060264796 Flick et al. Nov 2006 A1
20070021697 Ginther et al. Jan 2007 A1
20070027414 Hoffman et al. Feb 2007 A1
20070032755 Walsh Feb 2007 A1
20070044801 Mathis et al. Mar 2007 A1
20070066946 Haggstrom et al. Mar 2007 A1
20070078366 Haggstrom et al. Apr 2007 A1
20070129707 Blott et al. Jun 2007 A1
20070135777 Greene et al. Jun 2007 A1
20070167884 Mangrum et al. Jul 2007 A1
20070185426 Ambrosio et al. Aug 2007 A1
20070185463 Mulligan Aug 2007 A1
20070219497 Johnson et al. Sep 2007 A1
20070219513 Lina et al. Sep 2007 A1
20070219532 Karpowicz et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070255193 Patel et al. Nov 2007 A1
20070265586 Joshi Nov 2007 A1
20080004549 Anderson et al. Jan 2008 A1
20080009812 Riesinger Jan 2008 A1
20080026023 Tauer et al. Jan 2008 A1
20080039763 Sigurjonsson et al. Feb 2008 A1
20080071207 de Luis et al. Mar 2008 A1
20080071214 Locke et al. Mar 2008 A1
20080076844 Van Sumeren et al. Mar 2008 A1
20080103462 Wenzel et al. May 2008 A1
20080103489 Dahners May 2008 A1
20080119802 Riesinger May 2008 A1
20090043268 Eddy et al. Feb 2009 A1
20090047855 Seth et al. Feb 2009 A1
20090125004 Shen et al. May 2009 A1
20090177051 Arons et al. Jul 2009 A1
20090204084 Blott et al. Aug 2009 A1
20090204085 Biggie et al. Aug 2009 A1
20090227968 Vess Sep 2009 A1
20090234307 Vitaris Sep 2009 A1
20090264807 Haggstrom et al. Oct 2009 A1
20090293887 Wilkes et al. Dec 2009 A1
20090299257 Long et al. Dec 2009 A1
20120220963 Hunt et al. Aug 2012 A1
20140163491 Schuessler et al. Jun 2014 A1
20150080788 Blott et al. Mar 2015 A1
Foreign Referenced Citations (105)
Number Date Country
550575 Mar 1986 AU
745271 Mar 2002 AU
755496 Dec 2002 AU
2005436 Jun 1990 CA
2468309 Jul 2003 CA
2560068 Oct 2005 CA
2651833 Nov 2007 CA
1545991 Nov 2004 CN
101277734 Oct 2008 CN
26 40 413 Mar 1978 DE
39 07 522 Apr 1990 DE
43 06 478 Sep 1994 DE
29 504 378 Sep 1995 DE
20 2006 007877 Jul 2006 DE
102005007016 Aug 2006 DE
0100148 Feb 1984 EP
0117632 Sep 1984 EP
0161865 Nov 1985 EP
0330373 Aug 1989 EP
0358302 Mar 1990 EP
0421465 Apr 1991 EP
0424165 Apr 1991 EP
0619105 Oct 1994 EP
0691113 Jan 1996 EP
0756854 Feb 1997 EP
1018967 Jul 2000 EP
2282788 Dec 2016 EP
1163907 Oct 1958 FR
2661821 Nov 1991 FR
692578 Jun 1953 GB
1574066 Sep 1980 GB
2195255 Apr 1988 GB
2 197 789 Jun 1988 GB
2 220 357 Jan 1990 GB
2 235 877 Mar 1991 GB
2 329 127 Mar 1999 GB
2 333 965 Aug 1999 GB
H08154964 Jun 1996 JP
H10356 Jan 1998 JP
2000-189427 Jul 2000 JP
2000210386 Aug 2000 JP
2002-078730 Mar 2002 JP
2003-116907 Apr 2003 JP
2004-160220 Jun 2004 JP
2006-141908 Jun 2006 JP
2006219776 Aug 2006 JP
2006239213 Sep 2006 JP
4129536 Aug 2008 JP
71559 Apr 2002 SG
8002182 Oct 1980 WO
8704626 Aug 1987 WO
90010424 Sep 1990 WO
9205755 Apr 1992 WO
1993000056 Jan 1993 WO
93009727 May 1993 WO
199415562 Jul 1994 WO
9420041 Sep 1994 WO
199420152 Sep 1994 WO
199514451 Jun 1995 WO
9605873 Feb 1996 WO
1997005838 Feb 1997 WO
199711658 Apr 1997 WO
9718007 May 1997 WO
9901173 Jan 1999 WO
9913793 Mar 1999 WO
0007653 Feb 2000 WO
2000061206 Oct 2000 WO
200102478 Jan 2001 WO
01034223 May 2001 WO
200189431 Nov 2001 WO
200185248 Nov 2001 WO
200220067 Mar 2002 WO
2002083046 Oct 2002 WO
2003017898 Mar 2003 WO
2003057071 Jul 2003 WO
2003057307 Jul 2003 WO
03070135 Aug 2003 WO
2003077989 Sep 2003 WO
2003086262 Oct 2003 WO
2003101385 Dec 2003 WO
2004047695 Jun 2004 WO
2004060413 Jul 2004 WO
2005025447 Mar 2005 WO
2005034797 Apr 2005 WO
2005051461 Jun 2005 WO
2005082435 Sep 2005 WO
2005091884 Oct 2005 WO
2005123170 Dec 2005 WO
2006012745 Feb 2006 WO
2007030599 Mar 2007 WO
2007031762 Mar 2007 WO
2007033679 Mar 2007 WO
2007041642 Apr 2007 WO
2007085396 Aug 2007 WO
2007120138 Oct 2007 WO
2008013869 Jan 2008 WO
2008013896 Jan 2008 WO
2008020209 Feb 2008 WO
2008041926 Apr 2008 WO
2008054312 May 2008 WO
2008063281 May 2008 WO
2008104609 Sep 2008 WO
2009019496 Feb 2009 WO
2009047524 Apr 2009 WO
2009071926 Jun 2009 WO
Non-Patent Literature Citations (88)
Entry
Louis C. Argenta, MD and Michael J. Morykwas, PHD; Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience; Annals of Plastic Surgery; vol. 38, No. 6, Jun. 1997; pp. 563-576.
Susan Mendez-Eatmen, RN; “When wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24.
James H. Blackburn II, MD et al.: Negative-Pressure Dressings as a Bolster for Skin Grafts; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457; Lippincott Williams & Wilkins, Inc., Philidelphia, PA, USA.
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK.
S.E. Greer, et al. “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487.
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639.
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80.
International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995.
PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999.
PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999.
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & Apr. 29, 1997.
PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997.
Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5.
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof.
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof.
Yusupov. Yu.N., et al; “Active Wound Drainage”, Vestnki Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof.
Davydov, Yu.A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirugi, Oct. 1988, pp. 48-52, and 8 page English translation thereof.
Davydov, Yu.A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof.
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63.
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, p. 24.
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2.
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534.
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81.
Arnljots, Bjöm et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213.
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221.
Svedman, P. et al: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous of Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133.
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986); pp. 94-96 (copy and certified translation).
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246.
G. {hacek over (Z)}ivadinovi?, V. ?uki?, {hacek over (Z)}. Maksimovi?, ?. Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (copy and certified translation).
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585.
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (copy and certified translation).
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370.
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513.
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I).
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax, ”Journal of the American Medical Association 64 (1915), pp. 1548-1549.
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211.
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”).
V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”).
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”).
V.A.C. ® Therapy Clinical Guidelines: A Reference Source for Clinicians; Jul. 2007.
Extended European Search Report for corresponding Application No. 201963739, dated Jan. 1, 2021.
Japanese Notice of Rejection for corresponding Application No. 2020-005250, dated Oct. 27, 2020.
Extended European Search Report corresponding to Application No. 171645070, dated Jul. 18, 2017.
International Search Report and Written Opinion date mailed Aug. 20, 2009; PCT International Application No. PCT/ JS2009/045743.
Askin, et al. .; “Minimally Invasive Total Knee Replacement Through a Mini-Midvastus Incision: An Outcome Study,” Surgical Technology International XIII, 2004; 231-8.
A. Dee, “The successful management of a dehisced surgical wound with TNP following Femoropopliteal bypass”, Journal of Wound Care, vol. 16, No. 1, Jan. 2007.
Ogazon, Use of Vacuum-Assisted Closure in the Treatment of Surgical Infection Sites Cir. Mar. 2006-Apr. 74(2): 107-13 (Spanish).
Timmenga, “The Effects of Mechanical Stress on Healing Skin Wounds: An Experimental Study in Rabbits Using Tissues Expansions,” British Journal of Plastic Surgery 1991; 44(7): 514-519.
Cunningham “Development of in-vitro Model to Simulate Dermal Wound Bed Interaction with GranuFoam and Gauze Dressing under Sub Atmospheric Pressure” RPT 111-05-02, Device Implant Innovations 2006.
Delalleau, A., et al., “Characterization of the Mechanical Properties of Skin by Inverse Analysis Combined with the Indentation Test” Journal of Biomechanics, 2006; pp. 1603-1610.
Pailler-Mattei, C., “Caracte; Risation Me' Canique et Tribologizue de la Peau Humain In Vivo”, 2004-31.
Khatyr, F., “Model of the Viscoelastic Behavior of Skin In Vivo and Study of Anisotropy”, Skin Research and Technology 2004; pp. 96-103.
Wilkes, “3D Strain Measurement in Soft Tissue: Demonstration of a Novel Inverse Finite Element Model Algorithm on MicroCT Images of a Tissue Phantom Exposed to Negative Pressure Wound Therapy,” Journal of the Mechanical Behavior of Biomedical Materials (2008), pp. 1-16.
Diridollou, “In vivo Model of the Mechanical Properties of the Human Skin under Suction”, Skin Research and Technology, 2000; 6:214-221.
Woo, “Structural Model to Describe the Non-Linear Stress-Strain Behavior for Parallel-Fibered Collagenous Tissues,” Journal of Biomechanical Engineering, Nov. 1989, vol. 111/361.
International Search Report and Written Opinion date mailed Oct. 20, 2009; PCT International Application No. PCT/ JS2009/045747.
International Search Report and Written Opinion date mailed Oct. 16, 2009; PCT International Application No. PCT/ JS2009/045752.
International Search Report and Written Opinion date mailed Oct. 26, 2009; PCT International Application No. PCT/ JS2009/045751.
International Search Report and Written Opinion date mailed Oct. 27, 2009; PCT International Application No. PCT/ JS2009/045744.
International Search Report and Written Opinion date mailed Oct. 14, 2009; PCT International Application No. PCT/ JS2009/045746.
International Search Report and Written Opinion date mailed Nov. 11, 2009; PCT International Application No. PCT/ JS2009/045754.
International Search Report and Written Opinion date mailed Oct. 21, 2009; PCT International Application No. PCT/ JS2009/045749.
International Search Report and Written Opinion date mailed Nov. 12, 2009; PCT International Application No. PCT/ JS2009/045753.
International Search Report and Written Opinion date mailed Feb. 25, 2010; PCT International Application No. PCT/ JS2009/045750.
International Search Report and Written Opinion date mailed Mar. 12, 2010; PCT International Application No. PCT/ JS2009/045755.
Product Information for OptSiteTM dressing. Accessed Aug. 14, 2011.
International Search Report and Written Opinion date mailed Aug. 30, 2011 for PCT International Application No. PCT/ JS2011/034300.
Uropean Search Report for EP 09770665.9, dated Feb. 25, 2015.
Canadian Examiner's Report for Corresponding Application No. 2980359, mailed Jul. 31, 2018.
A Prospective, Blinded, Randomized, Controlled Clinical Trial of Topical Negative Pressure Use in Skin Grafting, Elias Moisidis, Tim Heath, Catherine Boorer, Kevin Ho, Anand K. Deva, Sydney, Australia, From the Department of Plastic and Maxillofacial Surgery, Liverpool Hospital. Received for publication Mar. 25, 2003; revised Oct. 1, 2003.
The Vacuum Assisted Closure Device, A Method of Securing Skin Grafts and Improving Grafts Survival; Lynette A. Scherer, Md; Stephen Shiver, Md; Michael Chang, Md; J_ Wayne Meredith, Md; John T. Owings. Md; From the Departments of Surgery, University of California-Davis Medical Center, Sacramento (Ors. Sherer and Owings), and Wake Forest University Baptist Medical Center, Winston-Salem, NC (Ors. Shiver, Chang, and Meredith); Arch SurQNol 137, AuQ 2002; www.archsurQ.com.
Examination Report for corresponding EP 09770659.2, mailed Sep. 4, 2013.
Extended European Search Report for corresponding Eurpean Application No. 12171212.9 mailed Nov. 14, 2012.
European Search Report for EP 14182278.3 dated Jan. 7, 2015.
European Examination Report for corresponding EP09770663.4, mailed Aug. 9, 2013.
Chintamani V.S et al. : “Half Versus Full Vacuum Suction Drainage After Modified Radical Mastectomy for Breast Cancer- a Prospective Randomized Clinical Trial [ISRCTN24484328]”, Bmc Cancer, 2005, vol. 5, article 11; abstract.
Japanese Office Action corresponding to Application No. 2016104769, mailed Mar. 7, 2017.
European Search Report for corresponding Application No. 16171527.1 dated Dec. 9, 2016.
Communication pursuant to Rule 114(2) EPC for corresponding EP Application 09770664.2, mailed Aug. 22, 2013.
Canadian Office Action dated May 25, 2016, corresponding to Canada Application No. 2,725,945.
Mexican Office Action corresponding to Application No. MX/a/2010/013134, mailed Oct. 26, 2017.
Indian Examination Report for corresponding Application No. 9029/DELNP/2010, mailed Nov. 23, 2017.
Extended European Search Report for corresponding Application No. 161998968, mailed Mar. 1, 2017.
Japanese Notice of Rejection Corresponding to Application No. 2017-235283, mailed Aug. 6, 2019.
Chinese First Office Action for corresponding Application No. 202011083392.4, dated Aug. 2, 2021.
Office action for related U.S. Appl. No. 16/242,825, dated Oct. 27, 2021.
Office Action for related U.S. Appl. No. 16/278,638, dated Sep. 29, 2021.
Office Action for related U.S. Appl. No. 16/740,004, dated Oct. 4, 2021.
Related Publications (1)
Number Date Country
20200276055 A1 Sep 2020 US
Provisional Applications (11)
Number Date Country
61144067 Jan 2009 US
61121362 Dec 2008 US
61057807 May 2008 US
61057797 May 2008 US
61057810 May 2008 US
61057803 May 2008 US
61057805 May 2008 US
61057800 May 2008 US
61057802 May 2008 US
61057798 May 2008 US
61057808 May 2008 US
Divisions (1)
Number Date Country
Parent 12475285 May 2009 US
Child 13546161 US
Continuations (2)
Number Date Country
Parent 14309705 Jun 2014 US
Child 16875587 US
Parent 13546161 Jul 2012 US
Child 14309705 US